BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.
BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.